Markets Published July 25, 2016 12:04pm EDT | Updated November 23, 2017 5:01pm EST Tobira Therapeutics' Stock Loses Half Its Value After Trial Misses Primary Endpoint Comments By Tomi Kilgore MarketWatch Pulse